Limits...
Genetic association between PER3 genetic polymorphisms and cancer susceptibility: a meta-analysis.

Geng P, Ou J, Li J, Wang N, Xie G, Sa R, Liu C, Xiang L, Liang H - Medicine (Baltimore) (2015)

Bottom Line: We collected genetic data from 8 studies, providing 6149 individuals for rs1012477 and 5241 individuals for 4/5-repeat.For PER3 4/5-repeat variant, we found a moderate increase in risk of cancer among individuals with the 5-allele compared to individuals with the 4-allele, although this association was not statistically significant (homozygous model: odds ratio [OR] 1.17, 95% confidence interval [CI] 0.81-1.67; recessive model: OR 1.17, 95% CI 0.82-1.67).No substantial heterogeneity was revealed in this analysis.

View Article: PubMed Central - PubMed

Affiliation: From the Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, China.

ABSTRACT
The genes along the circadian pathways control and modulate circadian rhythms essential for the maintenance of physiological homeostasis through self-sustained transcription-translation feedback loops. PER3 (period 3) is a circadian pathway gene and its variants (rs1012477, 4/5-repeat) have frequently been associated with human cancer. The mixed findings, however, make the role of the 2 variants in cancer susceptibility elusive. We aimed in this article to clarify the association of PER3 variants with cancer. We collected genetic data from 8 studies, providing 6149 individuals for rs1012477 and 5241 individuals for 4/5-repeat. Based on the genotype and allele frequency, we chose the fixed-effects model to estimate risk of cancer. Overall analysis did not suggest a global role of rs1012477 in cancer susceptibility. For PER3 4/5-repeat variant, we found a moderate increase in risk of cancer among individuals with the 5-allele compared to individuals with the 4-allele, although this association was not statistically significant (homozygous model: odds ratio [OR] 1.17, 95% confidence interval [CI] 0.81-1.67; recessive model: OR 1.17, 95% CI 0.82-1.67). No substantial heterogeneity was revealed in this analysis. Our meta-analysis provides no evidence supporting a global association of PER3 genetic variants with the incidence of cancer.

Show MeSH

Related in: MedlinePlus

Meta-analysis for PER3 genetic variants and cancer susceptibility under the homozygous model. Each study was shown by a point estimate of the effect size (OR) (size inversely proportional to its variance) and its 95% confidence interval (95% CI) (horizontal lines). The diamonds represent the pooled ORs. CI = confidence interval, OR = odds ratio, PER3 = period 3.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4554033&req=5

Figure 2: Meta-analysis for PER3 genetic variants and cancer susceptibility under the homozygous model. Each study was shown by a point estimate of the effect size (OR) (size inversely proportional to its variance) and its 95% confidence interval (95% CI) (horizontal lines). The diamonds represent the pooled ORs. CI = confidence interval, OR = odds ratio, PER3 = period 3.

Mentions: Table 2 shows the ORs and 95% CIs for all models tested in this analysis. Based on 2965 cases and 3184 controls for rs1012477, the overall analysis did not show statistical evidence of a significant association between rs1012477 and cancer risk in any of the genetic models tested: homozygous model (GG vs CC: OR 0.94, 95% CI 0.67–1.31, Figure 2), heterogeneous model (CG vs CC: OR 1.02, 95% CI 0.92–1.14), dominant model (GG + CG vs CC: OR 1.02, 95% CI 0.91–1.13), recessive model (GG vs CG + CC: OR 0.93, 95% CI 0.66–1.29, Figure 3), allele model (G vs C: OR 1.01, 95% CI 0.92–1.11).


Genetic association between PER3 genetic polymorphisms and cancer susceptibility: a meta-analysis.

Geng P, Ou J, Li J, Wang N, Xie G, Sa R, Liu C, Xiang L, Liang H - Medicine (Baltimore) (2015)

Meta-analysis for PER3 genetic variants and cancer susceptibility under the homozygous model. Each study was shown by a point estimate of the effect size (OR) (size inversely proportional to its variance) and its 95% confidence interval (95% CI) (horizontal lines). The diamonds represent the pooled ORs. CI = confidence interval, OR = odds ratio, PER3 = period 3.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4554033&req=5

Figure 2: Meta-analysis for PER3 genetic variants and cancer susceptibility under the homozygous model. Each study was shown by a point estimate of the effect size (OR) (size inversely proportional to its variance) and its 95% confidence interval (95% CI) (horizontal lines). The diamonds represent the pooled ORs. CI = confidence interval, OR = odds ratio, PER3 = period 3.
Mentions: Table 2 shows the ORs and 95% CIs for all models tested in this analysis. Based on 2965 cases and 3184 controls for rs1012477, the overall analysis did not show statistical evidence of a significant association between rs1012477 and cancer risk in any of the genetic models tested: homozygous model (GG vs CC: OR 0.94, 95% CI 0.67–1.31, Figure 2), heterogeneous model (CG vs CC: OR 1.02, 95% CI 0.92–1.14), dominant model (GG + CG vs CC: OR 1.02, 95% CI 0.91–1.13), recessive model (GG vs CG + CC: OR 0.93, 95% CI 0.66–1.29, Figure 3), allele model (G vs C: OR 1.01, 95% CI 0.92–1.11).

Bottom Line: We collected genetic data from 8 studies, providing 6149 individuals for rs1012477 and 5241 individuals for 4/5-repeat.For PER3 4/5-repeat variant, we found a moderate increase in risk of cancer among individuals with the 5-allele compared to individuals with the 4-allele, although this association was not statistically significant (homozygous model: odds ratio [OR] 1.17, 95% confidence interval [CI] 0.81-1.67; recessive model: OR 1.17, 95% CI 0.82-1.67).No substantial heterogeneity was revealed in this analysis.

View Article: PubMed Central - PubMed

Affiliation: From the Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, China.

ABSTRACT
The genes along the circadian pathways control and modulate circadian rhythms essential for the maintenance of physiological homeostasis through self-sustained transcription-translation feedback loops. PER3 (period 3) is a circadian pathway gene and its variants (rs1012477, 4/5-repeat) have frequently been associated with human cancer. The mixed findings, however, make the role of the 2 variants in cancer susceptibility elusive. We aimed in this article to clarify the association of PER3 variants with cancer. We collected genetic data from 8 studies, providing 6149 individuals for rs1012477 and 5241 individuals for 4/5-repeat. Based on the genotype and allele frequency, we chose the fixed-effects model to estimate risk of cancer. Overall analysis did not suggest a global role of rs1012477 in cancer susceptibility. For PER3 4/5-repeat variant, we found a moderate increase in risk of cancer among individuals with the 5-allele compared to individuals with the 4-allele, although this association was not statistically significant (homozygous model: odds ratio [OR] 1.17, 95% confidence interval [CI] 0.81-1.67; recessive model: OR 1.17, 95% CI 0.82-1.67). No substantial heterogeneity was revealed in this analysis. Our meta-analysis provides no evidence supporting a global association of PER3 genetic variants with the incidence of cancer.

Show MeSH
Related in: MedlinePlus